The purpose of this study is to determine whether SLx-4090 in combination with statin therapy will reduce LDL-C in patients with hyperlipidemia more effectively than statin therapy alone.

1. LDL-C after 12 weeks of treatment
2. Safety and tolerability
3. Plasma levels of SLx-4090

Inclusion Criteria:

• LDL-C > or = 100 mg/dL
• On stable statin therapy for at least 6 weeks

Exclusion Criteria:

• Coronary heart disease or risk factors for CHD